- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Operationalizing Bispecifics in Multiple Myeloma
Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.
In this special episode of Managed Care Cast, the executive editor of The American Journal of Managed Care®, Mary Caffrey, speaks with Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology's Nashville-Midtown Center for Blood Cancers, about the use of bispecific antibodies to treat patients with multiple myeloma, the importance of caregivers for this regimen, how the entire staff plays a role, the common adverse events patients need to be looking out for, and more.
Our conversation keys on themes from the recent article, “Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination,”1 led by Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, who is clinical pharmacy manager for the University of Kansas Health System. Sandahl was a coauthor on the paper and joins us for the first part of today’s podcast.
For the second part, Byrne, who was previously with Vanderbilt University Medical Center, shared why for some patients, the community oncology clinic is the only way to gain access to these life-saving treatments.
Both guests offer practical advice for bringing bispecifics to the community to help fellow physicians, and ultimately, patients.
Reference
Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. Seamless navigation of bispecific therapies: optimizing management and outpatient access with a focus on coordination. JADPRO. Published online September 11, 2024. https://doi.org/10.6004/jadpro.2024.15.8.15
Listen above or on one of these podcast services:
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More
